-
00:00
1.
index 1
-
00:27
2.
METTL1-mediated m7G modification promotes lenvatinib resistance in HCC
-
01:03
3.
m7G function
-
01:05
4.
METTL1-mediated m7G modification promotes lenvatinib resistance in HCC
-
03:11
5.
m7G function
-
06:39
6.
TRAC-seq
-
09:33
7.
Screening of regulatory factors for Lenvatinib resistance
-
13:54
8.
Screening of regulatory factors for Lenvatinib resistance
-
26:37
9.
METTL1-induced tRNA m7G modification regulates the Lenvatinib sensitivity
-
40:51
10.
METTL1-induced tRNA m7G modification regulates the Lenvatinib sensitivity
-
50:53
11.
m7G tRNA modification upregulates translation activity in LR cells
-
52:27
12.
** after 20241028 lab meeting.pptx
-
52:33
13.
Puromycin
-
52:46
14.
Puromycin
-
53:28
15.
** after 20241028 lab meeting.pptx
-
53:42
16.
m7G tRNA modification upregulates translation activity in LR cells
-
58:52
17.
m7G tRNA modification upregulates translation activity in LR cells
-
1:02:33
18.
m7G tRNA modification sustains LR by EGFR translation
-
1:08:37
19.
m7G tRNA modification sustains LR by EGFR translation
-
1:11:04
20.
m7G tRNA modification sustains LR by EGFR translation
-
1:18:18
21.
EGFR is a key METTL1 target that mediates LR in HCC
-
1:18:18
22.
m7G tRNA modification sustains LR by EGFR translation
-
1:18:21
23.
EGFR is a key METTL1 target that mediates LR in HCC
-
1:19:05
24.
EGFR is a key METTL1 target that mediates LR in HCC
-
1:19:26
25.
METTL1 promotes lenvatinib resistance in vivo
-
1:25:00
26.
METTL1 promotes lenvatinib resistance in vivo
-
1:26:27
27.
Targeting METTL1 effectively retards LR in vivo
-
1:30:41
28.
Targeting METTL1 effectively retards LR in vivo
-
1:30:57
29.
Targeting METTL1 effectively retards LR in vivo
-
1:31:01
30.
Targeting METTL1 effectively retards LR in vivo
-
1:32:35
31.
Slide 20
-
1:32:36
32.
Targeting METTL1 effectively retards LR in vivo
-
1:32:50
33.
20241028 lab meeting 楷軒.pptx